CU20110245A7 - Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) - Google Patents

Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

Info

Publication number
CU20110245A7
CU20110245A7 CU20110245A CU20110245A CU20110245A7 CU 20110245 A7 CU20110245 A7 CU 20110245A7 CU 20110245 A CU20110245 A CU 20110245A CU 20110245 A CU20110245 A CU 20110245A CU 20110245 A7 CU20110245 A7 CU 20110245A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
regf
treatment
gangliosids
neugcgm3
Prior art date
Application number
CU20110245A
Other languages
English (en)
Other versions
CU24070B1 (es
Inventor
Palomo Adys González
Pérz Adriana Carr
Monzón Kalet León
Santana Rancés Blanco
Alvarez María Del Carmen Barroso
Abraham Amparo Emilia Macías
Casimiro José Enrique Montero
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47435671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110245(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CU20110245A priority Critical patent/CU24070B1/es
Priority to UAA201408435A priority patent/UA111403C2/uk
Priority to NZ627012A priority patent/NZ627012B2/en
Priority to BR112014015693-0A priority patent/BR112014015693B1/pt
Priority to JP2014549356A priority patent/JP6027137B2/ja
Priority to CA2855182A priority patent/CA2855182C/en
Priority to MYPI2014701762A priority patent/MY185138A/en
Priority to PE2014001031A priority patent/PE20142328A1/es
Priority to AU2012361321A priority patent/AU2012361321C1/en
Priority to PCT/CU2012/000007 priority patent/WO2013097834A1/es
Priority to SG11201403014XA priority patent/SG11201403014XA/en
Priority to MX2014007919A priority patent/MX359476B/es
Priority to ES12806334.4T priority patent/ES2694324T3/es
Priority to KR1020147017242A priority patent/KR101703637B1/ko
Priority to CN201280062315.8A priority patent/CN103998098B/zh
Priority to EP12806334.4A priority patent/EP2805747B1/en
Priority to US14/369,435 priority patent/US9790279B2/en
Priority to EA201491284A priority patent/EA030346B1/ru
Priority to TR2018/16232T priority patent/TR201816232T4/tr
Priority to TW101146617A priority patent/TWI523663B/zh
Priority to ARP120105011 priority patent/AR089490A1/es
Publication of CU20110245A7 publication Critical patent/CU20110245A7/es
Priority to TNP2014000203A priority patent/TN2014000203A1/en
Priority to CL2014001236A priority patent/CL2014001236A1/es
Priority to PH12014501202A priority patent/PH12014501202A1/en
Priority to CO14134694A priority patent/CO6990729A2/es
Priority to IL233323A priority patent/IL233323B/en
Priority to ZA2014/05424A priority patent/ZA201405424B/en
Publication of CU24070B1 publication Critical patent/CU24070B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere, a composiciones farmacéuticas para el tratamiento de tumores malignos. Particularmente aquellos tumores que expresan los blancos REGF y gangliósido N-glicolil GM3 con el fin de potenciar el efecto terapéutico que producen las terapias contra dichos blancos por separado. Las composiciones farmacéuticas de la invención comprenden anticuerpos y/o vacunas contra cada uno de los blancos. Adicionalmente la prsente invención se refiere a los métodos para la aplicación de las composiciones de la invención.
CU20110245A 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) CU24070B1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
UAA201408435A UA111403C2 (uk) 2011-12-27 2012-04-12 ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ ПУХЛИН, ЕКСПРЕСУЮЧИХ EGFR І N-ГЛІКОЛІЛГАНГЛІОЗИД GM3 (NeuGсGM3)
TR2018/16232T TR201816232T4 (tr) 2011-12-27 2012-12-04 WGFR ve gangliyozid N-glikolil GM3(NeuGcGM3) ifade eden tümörlerin tedavisine yönelik farmasötik bileşimler.
ES12806334.4T ES2694324T3 (es) 2011-12-27 2012-12-04 Composiciones farmacéuticas para el tratamiento de tumores que expresan el REGF y el gangliósido N-glicolil GM3 (NeuGcGM3)
EP12806334.4A EP2805747B1 (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumours that express wgfr and ganglioside n-glycolyl gm3(neugcgm3)
JP2014549356A JP6027137B2 (ja) 2011-12-27 2012-12-04 Ｅｇｆｒ及びガングリオシドｎ−グリコリルｇｍ３（ｎｅｕｇｃｇｍ３）を発現する腫瘍の治療のための医薬組成物
CA2855182A CA2855182C (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3)
MYPI2014701762A MY185138A (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
PE2014001031A PE20142328A1 (es) 2011-12-27 2012-12-04 Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliosido n-glicolil gm3 (neugcgm3)
AU2012361321A AU2012361321C1 (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumours that express EGFR and ganglioside N-glycolyl GM3 (NEUGCGM3)
PCT/CU2012/000007 WO2013097834A1 (es) 2011-12-27 2012-12-04 COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIÓSIDO N-GLICOLIL GM3 (NeuGcGM3)
SG11201403014XA SG11201403014XA (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3)
MX2014007919A MX359476B (es) 2011-12-27 2012-12-04 Composiciones farmaceuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3).
NZ627012A NZ627012B2 (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3)
KR1020147017242A KR101703637B1 (ko) 2011-12-27 2012-12-04 Egfr 및 강글리오시드 n-글리콜릴 gm3 (neugcgm3)를 발현하는 종양의 치료를 위한 약학 조성물
CN201280062315.8A CN103998098B (zh) 2011-12-27 2012-12-04 用于治疗表达EGFR和N‑羟乙酰GM3神经节苷脂(NeuGcGM3)的肿瘤的药物组合物
BR112014015693-0A BR112014015693B1 (pt) 2011-12-27 2012-12-04 Composição, e, kit de reagentes
US14/369,435 US9790279B2 (en) 2011-12-27 2012-12-04 Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3)
EA201491284A EA030346B1 (ru) 2011-12-27 2012-12-04 Фармацевтические композиции для лечения опухолей, экспрессирующих egfr и n-гликолилганглиозид gm3 (neugcgm3)
TW101146617A TWI523663B (zh) 2011-12-27 2012-12-11 供治療表現表皮生長因子受體（ＥＧＦＲ）和ＧＭ３ Ｎ－羥乙醯基神經節苷酯（ＮｅｕＧｃＧＭ３）之腫瘤用的醫藥組成物
ARP120105011 AR089490A1 (es) 2011-12-27 2012-12-27 COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TUMORES QUE EXPRESAN REGF Y GANGLIOSIDO N-GLICOLIL GM3 (NeuGcGM3)
TNP2014000203A TN2014000203A1 (en) 2011-12-27 2014-05-06 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS EXPRESSING EGFR AND GM3 N- GLYCOLYL GANGLIOSIDE (NeuGcGM3)
CL2014001236A CL2014001236A1 (es) 2011-12-27 2014-05-12 Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos.
PH12014501202A PH12014501202A1 (en) 2011-12-27 2014-05-28 Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
CO14134694A CO6990729A2 (es) 2011-12-27 2014-06-20 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3)
IL233323A IL233323B (en) 2011-12-27 2014-06-23 Medical preparations for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
ZA2014/05424A ZA201405424B (en) 2011-12-27 2014-07-23 Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

Publications (2)

Publication Number Publication Date
CU20110245A7 true CU20110245A7 (es) 2013-08-29
CU24070B1 CU24070B1 (es) 2015-01-29

Family

ID=47435671

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110245A CU24070B1 (es) 2011-12-27 2011-12-27 Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

Country Status (26)

Country Link
US (1) US9790279B2 (es)
EP (1) EP2805747B1 (es)
JP (1) JP6027137B2 (es)
KR (1) KR101703637B1 (es)
CN (1) CN103998098B (es)
AR (1) AR089490A1 (es)
AU (1) AU2012361321C1 (es)
BR (1) BR112014015693B1 (es)
CA (1) CA2855182C (es)
CL (1) CL2014001236A1 (es)
CO (1) CO6990729A2 (es)
CU (1) CU24070B1 (es)
EA (1) EA030346B1 (es)
ES (1) ES2694324T3 (es)
IL (1) IL233323B (es)
MX (1) MX359476B (es)
MY (1) MY185138A (es)
PE (1) PE20142328A1 (es)
PH (1) PH12014501202A1 (es)
SG (1) SG11201403014XA (es)
TN (1) TN2014000203A1 (es)
TR (1) TR201816232T4 (es)
TW (1) TWI523663B (es)
UA (1) UA111403C2 (es)
WO (1) WO2013097834A1 (es)
ZA (1) ZA201405424B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327620T2 (de) * 1992-08-18 2000-08-03 Centro De Immunologia Molecular, Ciudad De La Habana Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
CN1103404A (zh) * 1993-03-01 1995-06-07 分子免疫中心 识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Also Published As

Publication number Publication date
AR089490A1 (es) 2014-08-27
KR20140100538A (ko) 2014-08-14
BR112014015693B1 (pt) 2023-03-21
MY185138A (en) 2021-04-30
JP2015506354A (ja) 2015-03-02
TWI523663B (zh) 2016-03-01
WO2013097834A1 (es) 2013-07-04
TN2014000203A1 (en) 2015-09-30
CA2855182C (en) 2018-06-12
CO6990729A2 (es) 2014-07-10
EA030346B1 (ru) 2018-07-31
TW201336509A (zh) 2013-09-16
UA111403C2 (uk) 2016-04-25
CU24070B1 (es) 2015-01-29
IL233323A0 (en) 2014-08-31
CN103998098B (zh) 2017-08-04
AU2012361321A1 (en) 2014-07-24
IL233323B (en) 2018-11-29
US9790279B2 (en) 2017-10-17
CN103998098A (zh) 2014-08-20
TR201816232T4 (tr) 2018-11-21
EP2805747A1 (en) 2014-11-26
ZA201405424B (en) 2016-02-24
MX2014007919A (es) 2014-07-30
US20140363494A1 (en) 2014-12-11
EP2805747B1 (en) 2018-10-17
SG11201403014XA (en) 2014-09-26
NZ627012A (en) 2016-01-29
BR112014015693A8 (pt) 2017-07-04
KR101703637B1 (ko) 2017-02-07
AU2012361321A8 (en) 2014-08-07
PH12014501202A1 (en) 2014-09-08
JP6027137B2 (ja) 2016-11-16
EA201491284A1 (ru) 2014-09-30
ES2694324T3 (es) 2018-12-19
PE20142328A1 (es) 2015-01-29
MX359476B (es) 2018-09-27
AU2012361321C1 (en) 2016-03-10
AU2012361321B2 (en) 2015-11-19
CA2855182A1 (en) 2013-07-04
CL2014001236A1 (es) 2014-08-08
BR112014015693A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
EP3236945A4 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
UY35399A (es) Conjugados de fármacos con anticuerpos
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
UY34347A (es) Proteínas de función dual para tratar trastornos metabólicos
CO2017003005A2 (es) Anticuerpos anti-mfi2
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112014015003A2 (pt) composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112013022234A2 (pt) emulsão de dodecafluorpentano como uma terapia de acidente vascular cerebral e isquemia
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
UY34078A (es) Composiciones farmacéuticas y métodos para tratar el cáncer
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
BR112017006779A2 (pt) composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
CO6990729A2 (es) Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósido n-glicolil gm3 (neugcgm3)
TH1401003675A (th) องค์ประกอบทางเภสัชกรรมสำหรับการรักษาเนื้องอกที่แสดง EGFR และ แกงกลิโอไซด์ N-ไกลโคลิล GM3 (NeuGcGM3)

Legal Events

Date Code Title Description
FG Grant of patent